GLPG - Galapagos to Host KOL Event on December 10 2023 at 11:00 AM PST to discuss new data presented at ASH 2023 | Benzinga
Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST. The in-person event will be held at the San Diego Marriott Gaslamp Quarter in the Presidio Ballroom B/C. To register as an in-person attendee, please click here. To register as a virtual attendee, please click here.
The event will feature the following KOLs who will review the results observed to date of the ongoing Phase 1/2 CD19 CAR-T studies with GLPG5201 (EUPLAGIA-1) and GLPG5101 (ATALANTA-1):
- Professor Matthew S. Davids, MD, MMSc – Associate Professor of Medicine at Harvard Medical School, Director of Clinical Research, Associate Director of the CLL Center
- Professor Paolo Ghia, MD, PhD – Professor of Medical Oncology, Director, Strategic Research Program on CLL, Università Vita-Salute San Raffaele, Milano, Italy
- Professor Sébastien Anguille – Head of Hematology, University of Antwerp, Belgium
- Professor Michael R. Bishop, MD, FACP, FASCO – Director, The David and Etta Jonas Center for Cellular Therapy, University of Chicago
The event will also include a discussion of the potential for CAR-T candidates, manufactured using the Galapagos Point-of-Care platform, to improve survival for patients with a broad range of B-cell malignancies. Galapagos leadership, including Paul Stoffels1, MD, CEO and Chairman, will provide updates on:
- EUPLAGIA-1 study with GLPG5201 (CD19 CAR-T) in relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation (RT)
- ATALANTA-1 study with GLPG5101 (CD19 CAR-T) in relapsed/refractory non-Hodgkin lymphoma (rrNHL)
A live question and answer will follow the formal presentations. For more information, please contact sofie.vangijsel@glpg.com and nathalie.siegel@glpg.com.
About Matthew S. Davids, MD, MMSc
After obtaining an AB cum laude in chemistry at Harvard College, Dr. Davids completed his MD cum laude at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Master in Medical Science (MMSc) at Harvard Medical School. He is an attending physician in the Division of Lymphoma, where he serves as the Director of Clinical Research, as well as Associate Director of the CLL Center. He is also an Associate Professor of Medicine at Harvard Medical School and attends on the inpatient hematologic malignancies service at Brigham and Women's Hospital. Dr. Davids has an active translational research program in CLL and non-Hodgkin lymphoma, focusing on studying apoptosis (in particular Bcl-2 biology) in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of Bcl-2, B cell receptor pathway kinases, and other novel agents, as well as utilizing checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.
About Paolo Ghia, MD, PhD
Paolo Ghia received his MD from the University of Torino, Italy, and received his PhD working at the Basel Institute for Immunology, Switzerland, studying B lymphocyte development. Next, he studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly of follicular lymphoma at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.
He is now working in Milano, as Professor of Medical Oncology at the Università ...